UK Price Comparison: Wegovy vs Mounjaro vs Ozempic Facts
Wegovy or Mounjaro or Ozempic: Understanding Your UK Treatment Options
When comparing Wegovy, Mounjaro, or Ozempic in the UK, understanding their distinct purposes is crucial for making an informed choice. Wegovy (semaglutide) is specifically licensed by the MHRA for weight management in adults with a BMI of 30 or above, or BMI 27 with weight-related health conditions. Mounjaro (tirzepatide) combines GIP and GLP-1 receptor agonism, offering a dual mechanism approach that may provide different benefits for eligible patients.
Ozempic contains the same active ingredient as Wegovy (semaglutide) but is licensed exclusively for type 2 diabetes treatment, not weight management. Using Wegovy for weight management would constitute off-label use, which UK pharmacies cannot legally promote or supply for this purpose. This fundamental difference in licensing makes Wegovy or Mounjaro the appropriate options when specifically seeking weight management support through our GPhC-registered pharmacy.
Transparent Pricing for Wegovy or Mounjaro or Ozempic in the UK
EverydayMeds offers clear, competitive pricing for both Wegovy and Mounjaro without hidden fees or unexpected costs. Wegovy pricing starts at £79.99 for the 0.25mg starter dose when new customers apply code FIRST40 at checkout, progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Our bundle options provide convenience with the Intro Duo (0.25mg and 0.5mg) at £169.99 and Progress Duo (0.5mg and 1mg) at £189.99.
Mounjaro pricing reflects its dual mechanism formulation, with competitive rates available through the same streamlined ordering process. Returning customers can use code DOSE25 at checkout for continued savings on both treatments. Each price includes the complete service: clinical assessment, prescriber review, prescription, medication, and next-day cold-chain delivery, ensuring transparent value compared to other UK suppliers of these prescription-only medicines.
Clinical Evidence Supporting Wegovy or Mounjaro or Ozempic Choices
Understanding the clinical evidence helps inform decisions between these treatments. In the STEP clinical trials, patients taking Wegovy alongside diet and exercise achieved an average weight reduction of approximately 15% at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP 5 trial demonstrated sustained weight management benefits of approximately 15.2% at two years when treatment continued.
Mounjaro's clinical programme showed its dual GIP and GLP-1 mechanism may offer distinct benefits, though direct comparison trials between Wegovy and Mounjaro have not been conducted with identical trial designs or populations. Both treatments require ongoing commitment, as the STEP 1 extension study showed patients regained approximately two-thirds of lost weight within one year of stopping treatment, emphasising that weight management represents a long-term commitment rather than a short-term intervention.
How Wegovy or Mounjaro or Ozempic Work Differently
The mechanism differences between these treatments influence their suitability for different patients. Wegovy works as a GLP-1 receptor agonist, mimicking the natural hormone that signals fullness to your brain and may reduce food cravings by acting on appetite centres. Mounjaro combines GLP-1 action with GIP (glucose-dependent insulinotropic polypeptide) receptor activation, creating dual hormone pathway stimulation that may provide different appetite and metabolism effects. Ozempic uses the same semaglutide mechanism as Wegovy but in formulations and doses specifically designed for diabetes management rather than weight management. This fundamental difference in intended use makes Wegovy or Mounjaro the appropriate choices when seeking licensed weight management support. Your EverydayMeds prescriber can evaluate which mechanism may suit your individual health profile and treatment goals during the clinical assessment process.
Streamlined Ordering Process for Wegovy or Mounjaro or Ozempic
EverydayMeds simplifies access to both Wegovy and Mounjaro through an identical ordering pathway that takes approximately three minutes to complete. The online clinical assessment evaluates your suitability for either treatment option, allowing your prescriber to recommend the most appropriate choice based on your individual circumstances, medical history, and treatment preferences. Once submitted, prescriber review typically takes three working days, with express 24-hour review available for urgent requirements. Following prescription approval, next-day delivery ensures rapid treatment commencement through our temperature-controlled cold-chain logistics. The same discount codes (FIRST40 for new customers, DOSE25 for returning patients) apply at checkout regardless of whether you're prescribed Wegovy or Mounjaro, maintaining consistent value across both treatment options.
Storage and Practical Considerations for Wegovy or Mounjaro or Ozempic
Storage requirements differ between Wegovy and Mounjaro, potentially influencing your choice based on lifestyle factors. Wegovy pens must be stored in the refrigerator at 2-8°C before first use but offer superior travel convenience, remaining stable at room temperature below 30°C for up to six weeks once removed from refrigeration. Mounjaro requires more careful temperature management, with only 21 days of room temperature stability, making Wegovy advantageous for frequent travellers or those with limited refrigeration access. Both treatments use pre-filled FlexTouch pen systems for once-weekly injection, with mandatory dose escalation schedules that cannot be skipped. Wegovy follows a 20-week escalation from 0.25mg to the 2.4mg maintenance dose, whilst Mounjaro has its own specific titration schedule designed to optimise tolerability and effectiveness.
Cost-Effective Bundles for Wegovy or Mounjaro or Ozempic Treatment Continuity
Planning ahead with our bundle packages ensures treatment continuity whilst providing convenient delivery scheduling for both Wegovy and Mounjaro. The Intro Trio bundle (0.25mg, 0.5mg, and 1mg Wegovy) costs £299.99, covering your first 12 weeks of treatment with a single order and delivery. For patients reaching maintenance doses, the Ultimate Stability Trio provides three months of 2.4mg Wegovy supply for £649.99, reducing the frequency of reordering and ensuring consistent medication availability.
Bundle options eliminate the concern about dose progression timing, as you'll have the next escalation dose ready when needed. This approach proves particularly valuable given the mandatory escalation schedule that cannot be accelerated or delayed without compromising treatment effectiveness. Both new customer (FIRST40) and returning customer (DOSE25) discount codes apply to bundle purchases, maintaining the same competitive pricing advantage across single pens and multi-pen packages for both Wegovy and Mounjaro treatment pathways.
Expert Guidance for Your Wegovy or Mounjaro or Ozempic Decision
EverydayMeds clinical team guidance ensures you receive the most suitable treatment from our available options. During your assessment, our prescribers consider factors including your BMI, existing health conditions, previous weight management attempts, lifestyle requirements, and treatment preferences when recommending between Wegovy and Mounjaro. This personalised approach recognises that both prescription-only medicines can be effective, but individual patient factors may make one more suitable than the other. Remember to apply your discount code (FIRST40 for new customers, DOSE25 for returning patients) at checkout to access our competitive pricing. Start your assessment today at https://everydaymeds.co.uk/collections/wegovy and take the first step toward expert-guided weight management support. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment aligns best with your individual circumstances and goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
